The Limited Effect of a History of COVID-19 on Antibody Titers and Adverse Reactions Following BNT162b2 Vaccination: A Single-Center Prospective Study.

Background and Objectives: The need for, and ideal frequency of, the vaccination against coronavirus disease 2019 (COVID-19) of previously infected individuals have not yet been sufficiently evaluated. The aim of this study was to examine the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody status and adverse reactions after vaccination among medical staff with or without a history of COVID-19. Materials and Methods: A single-center prospective study was performed at Fukuoka University Chikushi Hospital. We investigated the presence of the anti-SARS-CoV-2 antibody titer among medical staff before and after mRNA vaccination with the BNT162b2. The levels of immunoglobulin G antibody were quantitatively measured at six points-before vaccination, after the first vaccination, at three points after the second vaccination, and finally, after the third vaccination-and the levels were then compared based on the COVID-19 infection history. Results: The previously infected (before the first vaccination) subjects (n = 17) showed a marked increase in antibody titers two weeks after the first vaccination and four weeks after the second vaccination. Although they were able to maintain a certain level of antibody titers until 30 weeks after the second vaccination, the titers fell in the same way as observed in the non-infected subjects. The subjects who did not receive the third vaccination due to adverse reactions to previous vaccines (n = 1) or who were positive for COVID-19 prior to the third vaccination (n = 2) were excluded from the subsequent analyses. Among non-infected subjects (n = 36), smokers had lower peak antibody titers than the others. The previously infected subjects had a significantly higher incidence of adverse reactions after the first vaccination but had a similar incidence of adverse reactions after the second and third vaccinations compared to the non-infected subjects. Conclusions: A history of COVID-19 may influence only the initial increase in anti-SARS-CoV-2 antibody titers and the occurrence of adverse reactions after the first vaccination.

[The application of fluorescence in situ hybridization to the peripheral-blood preparations].

The hematologic malignancy with specific chromosomal/genetic abnormality is separately classified by the WHO classification of tumors hematopoietic and lymphoid tissues. The chromosomal abnormalities, t (9; 22), t (8; 21), t (15; 17) and inv (16) are especially important for the establishment of therapeutic strategy and prognostication. We examined in this study, five cases were analyzed, because abnormal cells were recognized by the differential white blood count of the peripheral-blood and specific chromosomal abnormalities were suspected. Whether peripheral-blood preparations after May-Grünwald Giemsa staining could be used for fluorescence in situ hybridization (FISH). The fusion signals were detected in the high rate by using a peripheral-blood specimen in four cases, except for one case that had no specific chromosomal abnormality.